Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project
Abstract Purpose Targeted treatment and immunotherapy, both adjuvant treatment options, come with a certain toxicity and can cause severe side effects. To date, data about the underlying reasons for patients to accept or reject specific types of adjuvant therapy is scarce. Therefore, this study inve...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-12-01
|
| Series: | Journal of Cancer Research and Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00432-024-06014-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823863263045091328 |
|---|---|
| author | Toni Maria Janke Laura Moysig Christine Blome Katharina C. Kähler |
| author_facet | Toni Maria Janke Laura Moysig Christine Blome Katharina C. Kähler |
| author_sort | Toni Maria Janke |
| collection | DOAJ |
| description | Abstract Purpose Targeted treatment and immunotherapy, both adjuvant treatment options, come with a certain toxicity and can cause severe side effects. To date, data about the underlying reasons for patients to accept or reject specific types of adjuvant therapy is scarce. Therefore, this study investigates the motives of melanoma patients for tolerating or rejecting adjuvant therapy and its side effects. Methods We conducted semi-structured interviews with a subsample of patients to investigate the underlying reasons for treatment decisions in a quantitative treatment-trade off study. Categorisation was conducted using qualitative content analysis. Results The 17 participants had a mean age of 55.5 years and 12 were female. The final category system covered three clusters. The cluster “type of therapy and therapy process” described therapy-related aspects that affect acceptability of adjuvant treatments. Prospect of treatment benefit and side effects were important aspects. Route of administration and physician visits should be convenient. The cluster “way of living” described the influence that activities and circumstances of life organisation have on acceptability. Participants wished treatment to affect everyday life as little as possible. Maintaining sufficient quality of life was mentioned to be crucial. The cluster “emotions and feelings” described optimism and hope but also mental strain originating from possible treatment options. Conclusion Patients in our study indicate high willingness to undergo adjuvant therapy, even when facing toxicity. The evaluation of potential side effects and prospects of treatment benefit is highly individual. Therefore, it is important to consider personal patient preferences to make appropriate and shared decision-making. |
| format | Article |
| id | doaj-art-41473f8d9ec843309aca27e4dd69e6ad |
| institution | Kabale University |
| issn | 1432-1335 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Springer |
| record_format | Article |
| series | Journal of Cancer Research and Clinical Oncology |
| spelling | doaj-art-41473f8d9ec843309aca27e4dd69e6ad2025-02-09T12:10:20ZengSpringerJournal of Cancer Research and Clinical Oncology1432-13352024-12-01151111310.1007/s00432-024-06014-8Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A projectToni Maria Janke0Laura Moysig1Christine Blome2Katharina C. Kähler3Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE)Department of Dermatology, University Hospital Schleswig-Holstein (UKSH)Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE)Department of Dermatology, University Hospital Schleswig-Holstein (UKSH)Abstract Purpose Targeted treatment and immunotherapy, both adjuvant treatment options, come with a certain toxicity and can cause severe side effects. To date, data about the underlying reasons for patients to accept or reject specific types of adjuvant therapy is scarce. Therefore, this study investigates the motives of melanoma patients for tolerating or rejecting adjuvant therapy and its side effects. Methods We conducted semi-structured interviews with a subsample of patients to investigate the underlying reasons for treatment decisions in a quantitative treatment-trade off study. Categorisation was conducted using qualitative content analysis. Results The 17 participants had a mean age of 55.5 years and 12 were female. The final category system covered three clusters. The cluster “type of therapy and therapy process” described therapy-related aspects that affect acceptability of adjuvant treatments. Prospect of treatment benefit and side effects were important aspects. Route of administration and physician visits should be convenient. The cluster “way of living” described the influence that activities and circumstances of life organisation have on acceptability. Participants wished treatment to affect everyday life as little as possible. Maintaining sufficient quality of life was mentioned to be crucial. The cluster “emotions and feelings” described optimism and hope but also mental strain originating from possible treatment options. Conclusion Patients in our study indicate high willingness to undergo adjuvant therapy, even when facing toxicity. The evaluation of potential side effects and prospects of treatment benefit is highly individual. Therefore, it is important to consider personal patient preferences to make appropriate and shared decision-making.https://doi.org/10.1007/s00432-024-06014-8Adjuvant therapyPatient preferencesQualitative interviewsMelanoma |
| spellingShingle | Toni Maria Janke Laura Moysig Christine Blome Katharina C. Kähler Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project Journal of Cancer Research and Clinical Oncology Adjuvant therapy Patient preferences Qualitative interviews Melanoma |
| title | Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project |
| title_full | Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project |
| title_fullStr | Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project |
| title_full_unstemmed | Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project |
| title_short | Preferences of melanoma patients to accept adjuvant therapy and toxicity – a qualitative substudy of the GerMelaTox-A project |
| title_sort | preferences of melanoma patients to accept adjuvant therapy and toxicity a qualitative substudy of the germelatox a project |
| topic | Adjuvant therapy Patient preferences Qualitative interviews Melanoma |
| url | https://doi.org/10.1007/s00432-024-06014-8 |
| work_keys_str_mv | AT tonimariajanke preferencesofmelanomapatientstoacceptadjuvanttherapyandtoxicityaqualitativesubstudyofthegermelatoxaproject AT lauramoysig preferencesofmelanomapatientstoacceptadjuvanttherapyandtoxicityaqualitativesubstudyofthegermelatoxaproject AT christineblome preferencesofmelanomapatientstoacceptadjuvanttherapyandtoxicityaqualitativesubstudyofthegermelatoxaproject AT katharinackahler preferencesofmelanomapatientstoacceptadjuvanttherapyandtoxicityaqualitativesubstudyofthegermelatoxaproject |